

A

SENNIGER, POWERS, LEAVITT & ROEDEL

ATTORNEYS AT LAW

ONE METROPOLITAN SQUARE
16TH FLOOR
ST. LOUIS, MISSOURI 63102
(314) 231-5400

FACSIMILE 314-231-4342
TELEX 6502697583 MCI

CABLE ADDRESS
PATENT

PATENTS, TRADEMARKS, COPYRIGHTS
AND RELATED MATTERS

EDWARD J. HEJLEK
KURT F. JAMES
VINCENT M. KEIL
WILLIAM E. LAHEY
DONALD G. LEAVITT
PAUL A. MADDOCK
MICHAEL G. MUNSELL
KATHLEEN M. PETRILLO
LAURA R. POLCYN
JOHN K. ROEDEL, JR.
JOSEPH A. SCHAPER**
PAUL A. STONE
RUDOLPH A. TELSCHER, JR.
SCOTT A. WILLIAMS

OF COUNSEL
IRVING POWERS
RICHARD G. HEYWOOD

February 12, 1998

JOSEPH N. SENNIGER
(921-1997)
JOHN R. AGOVINO
DEBBIE E. ALLEN
ROBERT M. BAIN
MICHAEL BLOSSER
RICHARD L. BRIDGE
J. BENNETT CLARK
CHARLES E. COHEN, PH.D.*
DAVID E. CRAWFORD, JR.
MATTHEW L. CUTLER
ROBERT M. EVANS, JR.
PAUL I. J. FLEISCHUT
ELIE H. GENDLOFF, PH.D.
MICHAEL E. GODAR
CHRISTOPHER M. GOFF
DAVID M. GRYTE

*VIRGINIA ONLY
**TEXAS ONLY

UTILITY PATENT APPLICATION TRANSMITTAL
(new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket Number: SRL 6067
First Named Inventor: Gary S. Jacob, et al
Express Mail Label Number: EM174420966US
Total Pages: 65

TO: Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

APPLICATION ELEMENTS

1. ☒ Fee Transmittal Form
(original and duplicate)
2. ☒ Specification [Total Pages 62]
3. ☒ Drawings [Total Sheets 3]
4. Oath or Declaration [Total Pages]
 - a. ☐ Newly executed (original or copy)
☐ New (unexecuted)
 - b. ☐ Copy from a prior application
(for continuation/divisional with
Box 17 completed)
 - i. ☐ DELETION OF INVENTOR(s)
Signed statement attached
deleting inventor(s) named
in prior application.
5. ☐ Incorporation By Reference
(useable if Box 4b is marked)
The entire disclosure of the prior application, from
which a copy of the oath or declaration is supplied
under Box 4b, is considered as being part of the
disclosure of the accompanying application and is hereby
incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above
copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ IDS with PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard
14. ☐ Small Entity Statement(s)
☐ Statement filed in prior application; status still
proper and desired
15. ☐ Certified Copy of Priority Document(s) if foreign
priority is claimed
16. ☐ Other: _____


**IF A CONTINUING APPLICATION, CHECK APPROPRIATE
BOX AND SUPPLY THE REQUISITE INFORMATION**

17. ☐ Continuation ☐ Divisional ☐ Continuation-in-Part
of prior application No.: ____/____
- ☒ Complete Application
based on provisional Application No. 60/041,221

CORRESPONDENCE ADDRESS

18. Correspondence Address: Customer Number 000321
Attention: Charles E. Cohen

Respectfully submitted,



Charles E. Cohen, Reg. No. 34,565

CEC/lep

FEE TRANSMITTAL

Application Number SRL 6067
Filing Date February 12, 1998
First Named Inventor Gary S. Jacob
Group Art Unit
Examiner Name
Attorney Docket Number SRL 6067

METHOD OF PAYMENT

1. ☐ The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345, in the name of Senniger, Powers, Leavitt & Roedel.

☐ The Commissioner is hereby authorized to charge any additional filing and claim fees under 37 CFR 1.16 and application processing fees under 37 CFR 1.17 to Deposit Account No. 19-1345, in the name of Senniger, Powers, Leavitt & Roedel.
2. ☒ Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345, in the name of Senniger, Powers, Leavitt & Roedel.

FEE CALCULATION

1. ☐ BASIC FILING FEE \$ 790.00 (Type: New Utility)
Entity Status: Large
2. ☒ CLAIM FEE \$ 1,406.00

Total Claims 69
Independent Claims 7
Multiple Dependent Claims _____
3. ☐ ADDITIONAL FEES \$ _____

☐ Surcharge - late filing fee or oath
☐ Surcharge - late provisional filing fee or cover sheet
☐ Extension for reply within _____ month
☐ Notice of Appeal
☐ Filing a Brief in Support of an appeal
☐ Request for Reexamination
☐ Petitions to the Commissioner
☐ Submission of Information Disclosure Statement
☐ Recording each patent assignment per property
☐ Other: _____

TOTAL AMOUNT OF PAYMENT \$ 2,196.00

Charles E. Cohen
Charles E. Cohen, Reg. No. 34,565

February 12, 1998
Date

CEC/lep

USE OF *N*-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL
COMPOUNDS IN COMBINATION THERAPY FOR TREATING
HEPATITIS VIRUS INFECTIONS

RELATED APPLICATION DATA

5 This application claims the benefit of priority of
U.S. provisional application serial number 60/041,221,
filed February 14, 1997.

BACKGROUND OF THE INVENTION

Field of the Invention

10 The present invention relates to methods and
compositions for treating hepatitis virus infections,
especially hepatitis B virus infections, in mammals,
especially humans. The methods comprise (1) administering
15 *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds
in combination with nucleoside antiviral agents,
nucleotide antiviral agents, mixtures thereof, or
immunomodulating/-immunostimulating agents, or (2)
administering *N*-substituted-1,5-dideoxy-1,5-imino-D-
20 glucitol compounds in combination with nucleoside
antiviral agents, nucleotide antiviral agents, or mixtures
thereof, and immunomodulating/immunostimulating agents.
Such combinations of anti-hepatitis viral agents show
unexpected efficacy in inhibiting replication and
secretion of hepatitis viruses in cells of mammals
25 infected with these viruses.

Description of Related Art

Hepatitis Viruses

 Hepatitis B Virus (HBV, HepB) is a causative agent of
acute and chronic liver disease including liver fibrosis,
30 cirrhosis, inflammatory liver disease, and hepatic cancer

that can lead to death in some patients (Joklik, Wolfgang K., *Virology*, Third Edition, Appleton & Lange, Norwalk, Connecticut, 1988 (ISBN 0-8385-9462-X)). Although effective vaccines are available, there are still more than 300 million people worldwide, i.e., 5% of the world's population, chronically infected with the virus (Locarnini, S. A., et. al., *Antiviral Chemistry & Chemotherapy* (1996) 7(2):53-64). Such vaccines have no therapeutic value for those already infected with the virus. In Europe and North America, between 0.1% to 1% of the population is infected. Estimates are that 15% to 20% of individuals who acquire the infection develop cirrhosis or another chronic disability from HBV infection. Once liver cirrhosis is established, morbidity and mortality are substantial, with about a 5-year patient survival period (Blume, H., E., et.al., *Advanced Drug Delivery Reviews* (1995) 17:321-331). It is therefore necessary and of high priority to find improved and effective anti-HBV anti-hepatitis therapies (Locarnini, S. A., et. al., *Antiviral Chemistry & Chemotherapy* (1996) 7(2): 53-64).

Other hepatitis viruses significant as agents of human disease include Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis Delta, Hepatitis E, Hepatitis F, and Hepatitis G (Coates, J. A. V., et.al., *Exp. Opin. Ther. Patents* (1995) 5(8):747-756). In addition, there are animal hepatitis viruses that are species-specific. These include, for example, those infecting ducks, woodchucks, and mice.

1,5-dideoxy-1,5-imino-D-glucitol Compounds

1,5-dideoxy-1,5-imino-D-glucitol (also known as 1-deoxynojirimycin, DNJ) and its N-alkyl derivatives are known inhibitors of the N-linked oligosaccharide processing enzymes alpha glucosidase I and II (Saunier et al., *J. Biol.Chem.* (1982) 257:14155-14161 (1982); Elbein, *Ann. Rev. Biochem.* (1987) 56:497-534). As glucose

analogs, they also have potential to inhibit glucose transport, glucosyl-transferases, and/or glycolipid synthesis (Newbrun et al., *Arch. Oral Biol.* (1983) 28: 516-536; Wang et al., *Tetrahedron Lett.* (1993) 34:403-406). Their inhibitory activity against glucosidases has led to the development of these compounds as anti-hyperglycemic agents and antiviral agents. See, for example, PCT International Publication WO 87/03903 and U.S. Patents 4,065,562; 4,182,767; 4,533,668; 4,639,436; 4,849,430; 4,957,926; 5,011,829; and 5,030,638.

Glucosidase inhibitors such as *N*-alkyl-1,5-dideoxy-1,5-imino-D-glucitol compounds wherein the alkyl group contains between three and six carbon atoms have been shown to be effective in the treatment of Hepatitis B infection (PCT International Publication WO 95/19172). For example, *n*-butyl-deoxynojirimycin (*n*-butyl-DNJ; *N*-butyl-1-5-dideoxy-1,5-imino-D-glucitol) is effective for this purpose (Block, T. M., *Proc. Natl. Acad. Sci. USA* (1994) 91:2235-2239; Ganem, B. *Chemtracts: Organic Chemistry* (1994) 7(2), 106-107). *N*-butyl-DNJ has also been tested as an anti-HIV-1 agent in HIV infected patients, and is known to be well tolerated. Another alpha glucosidase inhibitor, deoxynojirimycin (DNJ), has been suggested as an antiviral agent for use in combination with *N*-(phosphonoacetyl)-L-aspartic acid (PALA) (WO 93/18763). However, combinations of *N*-substituted-imino-D-glucitol derivatives and other antiviral agents for the treatment of hepatitis virus infections have not been previously disclosed or suggested.

Nucleoside and Nucleotide Antiviral Agents

Reverse transcriptase inhibitors, including the class of nucleoside and nucleotide analogs, were first developed as drugs for the treatment of retroviruses such as human immunodeficiency virus (HIV), the causative agent of AIDS.

Increasingly, these compounds have found use against other viruses, including both RNA and DNA viruses, via viral screening and chemical modification strategies.

Nucleoside and nucleotide analogs exert their antiviral

5 activities by inhibiting the corresponding DNA and RNA polymerases responsible for synthesis of viral DNA and RNA, respectively. Because viruses contain different forms of polymerases, the same nucleoside/nucleotide compound can have a dramatically different effect against
10 different viruses. For example, lamivudine (3TC™) appears to be useful against HBV infection, whereas zidovudine (AZT™) appears to have little use against the same virus (Gish, R.G., et al., *Exp. Opin. Invest. Drugs* (1995) 4(2):95-115).

15 Toxicity has been significant with some nucleoside analog antivirals. For example, clinical tests on the use of the nucleoside analog fialuridine (FIAU) for treatment of chronic hepatitis B were suspended recently due to drug-related liver failure leading to death in some
20 patients. Consequently, there is still a need for safer drug regimens for the treatment of hepatitis B infections and hepatitis (Mutchnick, M. G., et. al., *Antiviral Research* (1994) 24:245-257).

Immunomodulators and Immunostimulants

25 Immunomodulators/immunostimulators such as interferon alfa and other cytokines have been used for the treatment of HBV infection with promising results. Unfortunately, the response rates are lower than desired. Interferon treatment is currently approved by the FDA for
30 the treatment of Hepatitis B. Other immune system-affecting drug candidates are presently being investigated. These include thymic peptides for use in the treatment of chronic hepatitis B (CHB), isoprinosine, steroids, Schiff base-forming salicylaldehyde derivatives
35 such as Tucaresol, levamisol, and the like (Gish, R. G.,

et.al., *Exp. Opin. Invest. Drugs* (1995) 4(2):95-115;
Coates, J.A.V., et.al., *Exp. Opin. Ther. Patents* (1995)
5(8):747-765).

5 The use of *N*-substituted-imino-D-glucitol compounds
in combination with immunomodulating/immunostimulating
agents is novel.


SUMMARY OF THE INVENTION

As noted above, the combination of *N*-substituted-
imino-D-glucitol compounds and derivatives thereof with
10 other anti-hepatitis virus compounds has, to the present
inventor's knowledge, neither been suggested nor
disclosed. The use of two or more anti-viral agents to
provide improved therapy for the treatment of hepatitis B
virus infections is desirable due to the morbidity and
15 mortality of the disease. Combination therapy is also
desirable since it should reduce toxicity in patients as
it enables the physician to administer lower doses of one
or more of the drugs being given to a patient.
Combination therapy can also help to prevent the
20 development of drug resistance in patients (Wiltink, E. H.
H., *Pharmaceutish Weekblads Scientific Edition* (1992)
14(4A):268-274). The result of an improved efficacy
configuration combined with a relative lack of toxicity
and development of resistance would provide a much
25 improved drug treatment profile.

The present inventor has surprisingly discovered that
the combined use of *N*-substituted-1,5-dideoxy-1,5-imino-D-
glucitol compounds and nucleoside or nucleotide antiviral
compounds, or combinations thereof, and/or
30 immunomodulators/immunostimulants, results in unexpectedly
greater anti-hepatitis virus effectiveness of the
compounds compared to the combined antiviral activities
expected of the individual compounds alone. Whether this
is due to different mechanisms of action of the different
35 classes of drugs employed or some other biological

phenomenon is presently unclear.

Accordingly, in a first aspect, the present invention provides a method of treating a hepatitis virus infection in a mammal, comprising administering to said mammal a
5 first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



I

wherein:

10 R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C_1 to C_{20} , and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and
15 trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof,

20 wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.

In a second aspect, the present invention provides a method of treating a hepatitis B virus infection in a
25 mammal, comprising administering to said mammal from about 0.1 mg/kg/day to about 100 mg/kg/day of an *N*-substituted-

1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I, as above, and from about 0.1 mg/person/day to about 500 mg/person/day of a compound selected from the group consisting of a nucleoside antiviral compound, a
5 nucleotide antiviral, and mixtures thereof.

The present invention also provides a method of treating a hepatitis B virus infection in a human patient, comprising administering to said human patient from about 0.1 mg/kg/day to about 100 mg/kg/day of *N*-(*n*-nonyl-)-1,5-
10 dideoxy-1,5-imino-D-glucitol and from about 0.1 mg/person/day to about 500 mg/person/day of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

Also provided is a composition, comprising an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of
15 Formula I, as above, and an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof.

The invention also provides a pharmaceutical
20 composition, comprising a first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I, as above, and a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral
25 compound, and mixtures thereof, as well as a pharmaceutically acceptable carrier, diluent, or excipient.

The invention further provides a pharmaceutical composition for treating a hepatitis B virus infection in
30 a mammal, comprising from about 0.1 mg to about 100 mg of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I, as above, and from about 0.1 mg to about 500 mg of a compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral, and
35 mixtures thereof.

Also provided is a pharmaceutical composition for

treating a hepatitis B virus infection in a human patient,
comprising from about 0.1 mg to about 100 mg of *N*-(*n*-
nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, and from about
0.1 mg to about 500 mg of (-)-2'-deoxy-3'-thiocytidine-5'-
5 triphosphate.

In addition to the foregoing, the present invention
also provides methods and compositions like those listed
above, wherein the *N*-substituted-1,5-dideoxy-1,5-imino-D-
glucitol compounds of Formula I, nucleoside antiviral
10 compounds, nucleotide antiviral compounds, or mixtures of
nucleoside and nucleotide antiviral compounds, are used in
combination with immunomodulators, immunostimulators, or
mixtures of immunomodulators and immunostimulators.

In another aspect, the present invention also
15 provides methods and compositions like those listed before
the paragraph immediately above, wherein the *N*-substi-
tuted-1,5-dideoxy-1,5-imino-D-glucitol compounds of
Formula I are used in combination with immunomodulators,
immunostimulators, or mixtures of immunomodulators and
20 immunostimulators, but without nucleoside antiviral
compounds, nucleotide antiviral compounds, or mixtures of
nucleoside and nucleotide antiviral compounds.

Further scope of the applicability of the present
invention will become apparent from the detailed
25 description and drawings provided below. However, it
should be understood that the following detailed
description and examples, while indicating preferred
embodiments of the invention, are given by way of
illustration only since various changes and modifications
30 within the spirit and scope of the invention will become
apparent to those skilled in the art from this detailed
description.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects, features, and
35 advantages of the present invention will be better

understood from the following detailed description taken in conjunction with the accompanying drawings, all of which are given by way of illustration only, and are not limitative of the present invention, in which:

5 Figure 1 shows the anti-hepatitis B virus activity of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC) alone and in combination with *N*-nonyl-DNJ *in vitro*.

10 Figure 2 shows the plasma concentration of *N*-nonyl-DNJ versus dose of *N*-nonyl-DNJ for each animal in Example 4, from samples taken during dosing. Animals are indicated by unique letters, and a small amount of random noise has been added to the dose value so that overlapping values can be distinguished.

15 Figure 3 shows the slope of $\text{Log}(\text{IPDNA} + 10)$ to week versus dose. A distinct letter is used for each animal. The fitted line is from a four parameter logistic model. The parameters of the fitted curve and their approximate standard errors are shown on the plot.

DETAILED DESCRIPTION OF THE INVENTION

20 The following detailed description is provided to aid those skilled in the art in practicing the present invention. Even so, this detailed description should not be construed to unduly limit the present invention as modifications and variations in the embodiments discussed
25 herein can be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.

30 The contents of each of the references cited herein, including the contents of the references cited within these primary references, are herein incorporated by reference in their entirety.

35 The present inventor has discovered that combinations of *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds with anti-hepatitis virus nucleoside or nucleotide analogs, and/or immunomodulators/-

immunostimulants, are more effective in inhibiting hepatitis virus replication than that which would be expected via the combined use of the individual compounds.


The present invention thus provides pharmaceutical compositions and methods of treating hepatitis virus infections, especially hepatitis B virus infections, in humans, other mammals, and cells using a combination of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound with either an antiviral nucleoside, an antiviral nucleotide, mixtures thereof, and/or an immunomodulating or immunostimulating agent. The *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds have basic nitrogen atoms and may be used in the form of a pharmaceutically acceptable salt. Nucleosides and nucleotides useful in the present invention are substituted purine or pyrimidine heterocycles further substituted with R¹ at the 9 position in the case of purines or with R¹ at the 1 position in the case of pyrimidines. The immunomodulating and immunostimulating agents useful in the present invention include those that stimulate immune responses effective in controlling or eliminating viruses or other infectious agents. Non-limiting examples of such immunomodulating and immunostimulating agents include cytokines, peptide agonists, steroids, and classic drugs such as levamisole. The drug combinations of this invention may be provided to a cell or cells, or to a human or other mammalian patient, either in separate pharmaceutically acceptable formulations, formulations containing more than one therapeutic agent, or by an assortment of single agent and multiple agent formulations. However administered, these drug combinations form an anti-hepatitis virus effective amount of components.

As used herein, the term "anti-hepatitis-virus effective amount" refers to a combined amount of (1) an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound with either an antiviral nucleoside, an antiviral

nucleotide, a mixture of an antiviral nucleoside and an antiviral nucleotide, or an immunomodulating/-immunostimulating agent (or mixtures thereof), or (2) a combined amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound with an antiviral nucleoside, an
5 antiviral nucleotide, or a mixture thereof, and an immunomodulating/-immunostimulating agent (or mixtures thereof) effective in treating hepatitis virus infection. The antiviral effectiveness of the aforementioned
10 combinations may involve a variety of different phenomena associated with viral replication and assembly. These may include, for example, blocking hepatitis viral DNA synthesis; blocking viral transcription; blocking virion assembly; blocking virion release or secretion from
15 infected cells; blocking or altering viral protein function, including the function of viral envelope protein(s); and/or the production of immature or otherwise non-functional virions. The overall effect is an inhibition of viral replication and infection of
20 additional cells, and therefore inhibition of the progress of infection in the patient.

***N*-substituted-1,5-dideoxy-1,5-imino-D-glucose Compounds**

N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds useful in the present invention are represented
25 by structure I below:



I

wherein R is selected from arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₁ to C₂₀, preferably C₂ to C₁₄, more preferably C₆ to C₁₂. R can also be C₁ to C₂₀ alkyl, preferably C₂ to C₁₄, more preferably C₆ to C₁₂, containing 1 to 5, more preferably 1 to 3, most preferably 1 to 2, oxygen atoms, i.e., oxa derivatives. Preferred R oxa derivatives are 3-oxanonyl, 3-oxadecyl, 7-oxanonyl, and 7-oxadecyl. W, X, Y and Z are independently selected from hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

Representative *N*-substituted-imino-D-glucitol compounds useful in the present invention include, but are not limited to:

- N*-(*n*-hexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- 15 *N*-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
- 20 *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
- N*-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
- N*-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
- 25 *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- 30 *N*-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- 35 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

- N*-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
5 *N*-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
10 glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
15 tetrabutyrate;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
20 *N*-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
25 tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
30 *N*-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
35 tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

5 *N*-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

10 *N*-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

15 *N*-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrate; and

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate.

20 Preferred compounds are *N*-(*n*-nonyl)-1,5-dideoxy-1,5-
imino-D-glucitol and *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrate.

The *N*-substituted-imino-D-glucitol compounds useful
in the present invention can be prepared by methods well
25 known in the art as described in, for example, U.S.
Patents Nos. 4,182,767, 4,639,436, and 5,003,072, as well
as PCT International Publication WO 95/19172 and the
references cited therein. Methods for introducing oxygen
into alkyl side chains are disclosed in Tan et al., (1994)
30 *Glycobiology* 4(2):141-149. Non-limiting illustrative
preparation procedures are presented below in Examples 1
and 2.

In treating hepatitis virus infections, one can use
the anti-hepatitis virus combinations or individual
35 compounds of this invention in the form of salts derived
from inorganic or organic acids. These salts include but

are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

The basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; aralkyl halides such as benzyl and phenethyl bromides, and others. Water- or oil-soluble or dispersible products are thereby obtained as desired. The salts are formed by combining the basic compounds with the desired acid.

Other compounds of the combinations of this invention that are acids can also form salts. Examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium, or magnesium, or with organic bases or basic quaternary ammonium salts.


Compounds of the combinations of this invention may be acids or bases. As such, they may be used to form salts with one another. For example, the phosphoric acid form of (-)-2'-deoxy-3'-thiocyridine-5'-triphosphate will form a salt with the base form of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates. This type of salt can then be provided to the patient in a pharmaceutically acceptable

formulation or as a pure single salt.

In some cases, the salts can also be used as an aid in the isolation, purification, or resolution of the compounds of this invention.

5 Nucleosides and Nucleotides

Nucleosides and nucleotides useful in the present invention are purine (II) base compounds or pyrimidine (III) base compounds, or analogs such as compounds IV or V.



10 Position numbering for purines and pyrimidines is as shown in structures II and III. R¹ can be selected from hydroxyalkyl, hydroxyalkenyl, thiolalkyl, alkylthioalkyl, alkoxyalkyl, alkoxyalkenyl, heterocycle, heterocyclo-
15 alkyl, hydroxyalkylalkoxyalkyl, alkoxyalkylalkoxyalkyl, and cycloalkylalkyl. The purine compounds can be further substituted at positions 1, 2, 3, 6, 7, or 8 of the purine heterocycle, and the pyrimidine compounds can be
20 substituted at positions 2, 3, 4, 5, or 6 of the pyrimidine heterocycle. Such substituents can be selected from hydroxy, alkoxy, halo, thiol, amino, mono-substituted amino, di-substituted amino, and alkyl.

When used in combination with another radical when referring to the purines and pyrimidines useful in the present invention, the term "alkyl" means a straight or
25 branched chain hydrocarbon radical containing from 1 to 8

carbon atoms, preferably 1 to 4 carbon atoms. When used in combination with another radical, the term "alkenyl" means a straight or branched chain hydrocarbon radical having 1 or more double bonds, containing from 2 to 8 carbon atoms, preferably 1 to 4 carbon atoms. When used alone when referring to purines and pyrimidines useful in the present invention, the term "alkyl" means a straight or branched chain alkyl radical containing from six to 14 carbon atoms, preferably seven to 12 carbon atoms, and most preferably eight to 11 carbon atoms. The term "aryl" alone or in combination with another radical means a phenyl, naphthyl, or indenyl ring, optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, or nitro. "Alkanoyl" means branched or straight chain alkanecarbonyl having a chain length of C₁ to C₂₀, preferably C₂ to C₁₄, more preferably C₄ to C₁₀; "aroyl" means arylcarbonyl; and "trifluoroalkanoyl" means alkyl containing three fluoro substituents. "Halogen" means fluorine, chlorine, bromine, or iodine. "Thiol" means sulfur substituted with hydrogen (-SH). "Amino" means nitrogen with two hydrogen atoms; "monosubstituted amino" and "disubstituted amino" mean amino groups further independently substituted with one or more alkyl or arylalkyl groups. "Hydroxyalkyl" means an alkyl group substituted with one or more hydroxyl groups; "hydroxy-alkenyl" means an alkenyl group substituted with one or more hydroxyl groups; "thioalkyl" means an alkyl substituted with one or more thiol (SH) groups; "alkoxyalkyl" means an alkyl substituted with one or more alkyl ether groups; "alkoxyalkenyl" means an alkenyl group substituted with one or more alkyl ether groups; "hydroxyalkylalkoxyalkyl" means an alkoxyalkyl group substituted with a hydroxyalkyl group; "alkoxyalkyl-alkoxyalkyl" means an alkoxyalkyl group substituted with an alkoxyalkyl group; "cycloalkylalkyl" means an alkyl group substituted with a cycloalkyl group. The term

"heterocycle," alone or in combination, means a saturated or partially unsaturated 5 or 6-membered ring containing one or more oxygen, nitrogen, and/or sulfur heteroatoms. Said heterocycle can further be substituted with one to
5 four substituents, which can be independently, hydroxy, hydroxyalkyl, thiol, alkoxy, azido, nitro, a halogen atom, amino, mono-substituted amino, or disubstituted amino. Heterocycloalkyl means an alkyl group wherein one or more hydrogen atoms are replaced by a substituted or
10 unsubstituted heterocyclic ring.

Also included are the tautomers of the substituents on the compounds of the invention. Non-limiting examples of tautomers are ketone/enol tautomers, imino/amino tautomers, *N*-substituted imino/*N*-substituted amino
15 tautomers, thiol/thiacarbonyl tautomers, and ring-chain tautomers such as the five and six membered ring oxygen, nitrogen, sulfur, or oxygen- and sulfur- containing heterocycles also containing substituents alpha to the heteroatoms. Also specifically included in the present
20 invention are enantiomers and diastereomers, as well as racemates and isomeric mixtures of the compounds discussed herein.

Representative nucleoside and nucleotide compounds useful in the present invention include, but are not
25 limited to:
(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
30 (-)2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
35 iodocytosine triphosphate (FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-

- methyлуarcil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
5 2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
10 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
15 3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-
dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
20 acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
25 dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
stavudine;
2-deoxy-3'-thia-5-fluorocytidine;
30 2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.

A preferred compound is (-)-2'-deoxy-3'-thiocytidine-
5'-triphosphate (3TC).

- Synthetic methods for the preparation of nucleosides
35 and nucleotides useful in the present invention are
likewise well known in the art as disclosed in *Acta*

Biochim. Pol., **43**, 25-36 (1996); *Swed. Nucleosides Nucleotides* **15**, 361-378 (1996), *Synthesis* **12**, 1465-1479 (1995), *Carbohydr. Chem.* **27**, 242-276 (1995), *Chem. Nucleosides Nucleotides* **3**, 421-535 (1994), *Ann. Reports in Med. Chem.*, Academic Press; and *Exp. Opin. Invest. Drugs* **4**, 95-115 (1995).

The chemical reactions described in the references cited above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the scope of compounds disclosed herein. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials.

While nucleoside analogs are generally employed as antiviral agents as is, nucleotides (nucleoside phosphates) must sometimes have to be converted to nucleosides in order to facilitate their transport across cell membranes. An example of a chemically modified nucleotide capable of entering cells is S-1-3-hydroxy-2-phosphonylmethoxypropyl cytosine (HPMPC, Gilead Sciences).

Immunomodulators and Immunostimulants

A large number of immunomodulators and immunostimulants that can be used in the methods of the present invention are currently available. A list of these compounds is provided in Table 1, below.

Table 1

DRUG NAME

	AA-2G
5	adamantylamide dipeptide
	adenosine deaminase, Enzon
	adjuvant, Alliance
	adjuvants, Ribic
	adjuvants, Vaxcel
10	Adjuvax
	agelasphin-11
	AIDS therapy, Chiron
	algal glucan, SRI
	algammulin, Amutech
15	Anginlyc
	anticellular factors, Yeda
	Anticort
	antigastrin-17 immunogen, Ap
	antigen delivery system, Vac
20	antigen formulation, IDEC
	antiGnRH immunogen, Aphton
	Antiherpin
	Axibidol
	Aviron
25	azarole
	Bay-q-8939
	Bay-r-1005
	BCH-1393
	Betafectin
30	Biostim
	BL-001
	BL-009
	Broncostat
	Cantastim
35	CDRI-84-246
	cefodizime
	chemokine inhibitors, ICOS
	CMV peptides, City of Hope
	CN-5888
40	cytokine-releasing agent, St
	DREAS, Paradigm
	DISC TA-MSV
	JO7B
	IO1A
	IO1Z

5 ditiocarb sodium
 ECA-10-142
 ELS-1
 endotoxin, Novartis

10 FCE-20696
 FCE-24089
 FCE-24578
 FLT-3 ligand, Immunex
 FR-900483
 FR-900494
 FR-901235
 FTS-Zn

15 G-proteins, Cadus
 gludapcin
 glutaurine
 glycoposphopeptical
 GM-2
 GM-53
 GMDP

20 growth factor vaccine, Entrem
 H-BIG, NABI
 H-CIG, NABI
 HAB-439

25 Helicobacter pylori vaccine,
 herpes-specific immune facto
 HIV therapy, United Biomed
 HyperGAM+CP
 ImmuMax
 Immun BCG

30 immune therapy, Connective
 immunomodulator, Evans
 immunomodulators, Novacell
 imreg-1
 imreg-2

35 Indomune
 inosine pranobex
 interferon, Dong-A (alpha2)
 interferon, Genentech (gamma
 interferon, Novartis (alpha)

40 interleukin-12, Genetics Ins
 interleukin-15, Immunex
 interleukin-16, Research Cor
 ISCAR-1

45 J005X
 L-644257
 licoamarasminic acid
 LipoTher
 LX-409

50 LX-410
 LP-2307
 LT(R1926)
 LW-50020

55 MAF, Shionogi
 MDP derivatives, Merck
 met-enkephalin, TNI
 methylfurylbutyrolactones
 MIMP

	mirimostim
	mixed bacterial vaccine, Tem
	MM-1
5	moniliastat
	MPLA, Ribi
	MS-705
	murabutide
	murabutide, Vacsyn
10	muramyl dipeptide derivative
	muramyl peptide derivatives
	myelopid
	N-563
	NACOS-6
15	NH-765
	NISV, Proteus
	NPT-16416
	NT-002
	PA-485
20	PEFA-814
	peptides, Scios
	peptidoglycan, Fliva
	Perthon, Advanced Plant
	PGM derivative, Fliva
25	Pharmaprojects No. 1099
	Pharmaprojects No. 1426
	Pharmaprojects No. 1549
	Pharmaprojects No. 1585
	Pharmaprojects No. 1607
30	Pharmaprojects No. 1710
	Pharmaprojects No. 1779
	Pharmaprojects No. 2002
	Pharmaprojects No. 2060
	Pharmaprojects No. 2795
35	Pharmaprojects No. 3088
	Pharmaprojects No. 3111
	Pharmaprojects No. 3345
	Pharmaprojects No. 3467
	Pharmaprojects No. 3668
40	Pharmaprojects No. 3998
	Pharmaprojects No. 3999
	Pharmaprojects No. 4089
	Pharmaprojects No. 4188
	Pharmaprojects No. 4451
45	Pharmaprojects No. 4500
	Pharmaprojects No. 4689
	Pharmaprojects No. 4833
	Pharmaprojects No. 494
	Pharmaprojects No. 5217
50	Pharmaprojects No. 530
	pidotimod
	pimelaotide
	pinafide
	PMD-589
55	podophyllotoxin, Conpharm
	POL-509
	poly-ICLC
	poly-ICLC, Yamasa Shoyu
	PolyA-PolyU
	Polysaccharide A

5 protein A, Berlex Bioscience
PS34W0
pseudomonas MAbs, Teijin
Psomaglobin
PTL-78419
Pyrexol
pyriferone
Retrogen
10 Retropep
RG-003
RhinoStat
rifamexil
RM-06
Rollin
15 romurtide
RU-40555
RU-41821
rubella antibodies, ResCo
S-27609
20 SB-73
SDZ-280-636
SDZ-MRL-953
SK&F-107647
SLO4
25 SLO5
SM-4333
Solutein
SRI-62-834
SRL-172
30 ST-570
ST-789
staphage lysate
Stimulon
suppressin
35 T-150R1
T-LCEF
tabilautide
temurtide
40 Theradigm-HBV
Theradigm-HPV
Theradigm-HSV
THF, Pharm & Upjohn
THF, Yeda
45 thymalfasin
thymic hormone fractions
thymocartin
thymolymphotropin
thymopentin
thymopentin analogues
50 thymopentin, Peptech
thymosin fraction 3, Alpha
thymostimulin
thymotrinan
TMD-232
55 TO-115
transfer factor, Viragen
tuftsin, Selavo
ubenimex
Ulsastat

5	ANGG- CD-4+ Collag+ COLSF+ COM+ DA-A+ GAST- GF-TH+ GP-120-
10	IF+ IF-A+ IF-A-2+ IF-B+ IF-G+ IF-G-1B+
15	IL-2+ IL-12+ IL-15+ IM+ LHRH- LIPCOR+ LYM-B+ LYM-NK+ LYM-T+
20	OPI+ PEP+ PHG-MA+ RNA-SYN- SY-CW-
25	TH-A-1+ TH-5+ TNF+ UN
30	

Dosages

The *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds useful in the present invention can be administered to humans in an amount in the range of from about 0.1 mg/kg/day to about 100 mg/kg/day, more preferably from about 1 mg/kg/day to about 75 mg/kg/day, and most preferably from about 5 mg/kg/day to about 50 mg/kg/day.

The nucleoside or nucleotide antiviral compound, or mixtures thereof, can be administered to humans in an amount in the range of from about 0.1 mg/person/day to about 500 mg/person/day, preferably from about 10 mg/person/day to about 300 mg/person/day, more preferably from about 25 mg/person/day to about 200 mg/person/day, even more preferably from about 50 mg/person/day to about 150 mg/person/day, and most preferably in the range of from about 1 mg/person/day to about 50 mg/person/day.

Immunomodulators and immunostimulants useful in the present invention can be administered in amounts lower than those conventional in the art. For example, thymosin alpha 1 and thymosin fraction 5 are typically administered to humans for the treatment of HepB infections in an amount of about 900 $\mu\text{g}/\text{m}^2$, two times per week (*Hepatology* (1988) 8:1270; *Hepatology* (1989) 10:575; *Hepatology* (1991) 14:409; *Gastroenterology* (1995) 108:A1127). In the methods and compositions of the present invention, this dose can be in the range of from about 10 $\mu\text{g}/\text{m}^2$, two times per week to about 750 $\mu\text{g}/\text{m}^2$, two times per week, more preferably from about 100 $\mu\text{g}/\text{m}^2$, two times per week to about 600 $\mu\text{g}/\text{m}^2$, two times per week, most preferably from about 200 $\mu\text{g}/\text{m}^2$, two times per week to about 400 $\mu\text{g}/\text{m}^2$, two times per week. Interferon alfa is typically administered to humans for the treatment of HepC infections in an amount of from about 1×10^6 units/person, three times per week to about 10×10^6 units/person, three times per week (Simon et al., (1997) *Hepatology* 25:445-448). In the

methods and compositions of the present invention, this dose can be in the range of from about 0.1×10^6 units/person, three times per week to about 7.5×10^6 units/person, three times per week, more preferably from about 0.5×10^6 units/person, three times per week to about 5×10^6 units/person, three times per week, most preferably from about 1×10^6 units/person, three times per week to about 3×10^6 units/person, three times per week.

Due to the enhanced hepatitis virus antiviral effectiveness of these immunomodulators and immunostimulants in the presence of the *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds useful in the present invention, reduced amounts of other immunomodulators/immunostimulants can be employed in the methods and compositions disclosed herein. Such reduced amounts can be determined by routine monitoring of hepatitis virus in infected patients undergoing therapy. This can be carried out by, for example, monitoring hepatitis viral DNA in patients' serum by slot-blot, dot-blot, or PCR techniques, or by measurement of hepatitis surface or other antigens, such as the e antigen, in serum. Methods therefor are discussed in Hoofnagle et al., (1997) *New Engl. Jour. Med.* 336(5):347-356, and F.B. Hollinger in *Fields Virology*, Third Ed., Vol. 2 (1996), Bernard N. Fields et al., Eds., Chapter 86, "Hepatitis B Virus," pp. 2738-2807, Lippincott-Raven, Philadelphia, PA, and the references cited therein.

Patients can be similarly monitored during combination therapy employing *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds and nucleoside and/or nucleotide antiviral agents to determine the lowest effective doses of each.

The doses described above can be administered to a patient in a single dose or in proportionate multiple subdoses. In the latter case, dosage unit compositions can contain such amounts of submultiples thereof to make

up the daily dose. Multiple doses per day can also increase the total daily dose should this be desired by the person prescribing the drug.

Pharmaceutical Compositions

5 The compounds of the present invention can be formulated as pharmaceutical compositions. Such compositions can be administered orally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically in dosage unit formulations containing
10 conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein
15 includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pennsylvania (1975), and Liberman, H.A. and Lachman, L., Eds., *Pharmaceutical Dosage Forms*,
20 Marcel Decker, New York, N.Y. (1980).

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable
25 dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable
30 vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including
35 synthetic mono- or diglycerides. In addition, fatty acids

such as oleic acid are useful in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, and polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the compounds discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered *per os*, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-

aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the patient and the particular mode of administration.

Certain of the pharmaceutical compounds of this invention which are administered in accordance with the methods of the invention can serve as prodrugs to other compounds of this invention. Prodrugs are drugs that can be chemically converted *in vivo* or *in vitro* by biological systems into an active derivative or derivatives. Prodrugs are administered in essentially the same fashion as the other pharmaceutical compounds of the invention. Non-limiting examples are the esters of the *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of this invention.

Treatment Regimen

The regimen for treating a patient suffering from a

hepatitis virus infection with the compounds and/or compositions of the present invention is selected in accordance with a variety of factors, including the age, weight, sex, diet, and medical condition of the patient, the severity of the infection, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular compounds employed, and whether a drug delivery system is utilized.

Administration of the drug combinations disclosed herein should generally be continued over a period of several weeks to several months or years until virus titers reach acceptable levels, indicating that infection has been controlled or eradicated. As noted above, patients undergoing treatment with the drug combinations disclosed herein can be routinely monitored by measuring hepatitis viral DNA in patients' serum by slot-blot, dot-blot, or PCR techniques, or by measurement of hepatitis antigens, such as hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), in serum to determine the effectiveness of therapy. In chronic hepatitis B, for example, remissions are characterized by the disappearance of hepatitis B viral DNA, i.e., reduction to undetectable levels as measured by hybridization tests capable of detecting levels $\geq 10^5$ genomes per ml of serum, and HBeAg from serum despite the continued presence of HBsAg. These serologic events are followed by improvement in the biochemical and histologic features of the disease. The end point of successful treatment in most trials of antiviral therapy is the disappearance of HBeAg and viral DNA from serum. In patients in whom the e antigen disappears, remission is usually sustained, and results in an inactive HBsAg carrier state. Many patients eventually become HBsAg-negative (see Hoofnagle et al., (1997) *New Engl. Jour. Med.* 336(5):347-356 for a review).

Continuous analysis of the data obtained by these

methods permits modification of the treatment regimen during therapy so that optimal amounts of each component in the combination are administered, and so that the duration of treatment can be determined as well. Thus, 5 the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amounts of each of the antiviral compounds used in combination which together exhibit satisfactory anti-hepatitis virus effectiveness are administered, and so 10 that administration of such antiviral compounds in combination is continued only so long as is necessary to successfully treat the infection.

The following non-limiting examples serve to illustrate various aspects of the present invention.

15

Example 1

Preparation of

1,5-(butylimino)-1,5-dideoxy-D-glucitol

A solution of 1,5-dideoxy-1,5-imino-D-glucitol (5.14 g, 0.0315 mole), butyraldehyde (3.35 ml, 0.0380 20 mole) and Pd black (1 g) in 200 ml methanol was hydrogenated (60 psi/29°C/21 hrs.). After filtering the resulting mixture, the filtrate was concentrated *in vacuo* to an oil. The title compound was crystallized from acetone, and recrystallized from 25 methanol/acetone, m.p. ca. 132°C. The structure assignment was supported by NMR, infrared spectra and elemental analysis.

Analysis calcd. for $C_{10}H_{21}NO_4$: C, 54.78; H, 9.65; N, 6.39. Found: C, 54.46; H, 9.33; N, 6.46.

Example 2Preparation of1,5-(butylimino)-1,5-dideoxy-D-glucitol,
tetraacetate

5 Acetic anhydride (1.08 g, 0.0106 mole) was added
to the title compound of Example 1 (0.50 g, 0.0023
mole) in 5 ml pyridine and stirred for 17 days at
room temperature. The product was evaporated under
nitrogen gas. The resulting title compound was
10 purified by silica gel chromatography. Structure
assignment was supported by NMR, infrared spectra and
elemental analysis.

Analysis calcd. for $C_{18}H_{29}NO_8$: C, 55.80; H, 7.54;
N, 3.62. Found: C, 55.42; H, 7.50; N, 3.72.

15

Example 3Anti-Hepatitis B Virus Activity of(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC)Alone and in Combination with N-nonyl-DNJ

The anti-hepatitis B virus effect of
20 (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC) alone
and in combination with N-nonyl-DNJ was determined
according to Korba ((1996) *Antiviral Research* 29(1):49-
51), using the "combostat" strategy (Comstat Program,
Combostat Corp., Duluth, MN). The combostat method
25 involves serially diluting the IC-90 of each compound.
The IC-90 of N-nonyl-DNJ has been determined to be between
4 and 10 $\mu\text{g/ml}$ (T. Block and G. Jacob, unpublished
observation). The accepted IC-90 for 3TC in HepG 2.2.15
(2.2.15) cells is 300nM to 500nM (Doong et al. (1991)
30 *Proc. Natl. Acad. Sci. USA* 88:8495-8499).

2.2.15 cells, described in Sells et al. (1987) *Proc.*
Natl. Acad. Sci. USA 84:1005-1009, were maintained in RPMI
1640 medium (Gibco BRL, #31800-022) supplemented with 10%
fetal bovine serum, 200 $\mu\text{g/ml}$ G418 (Gibco BRL 066-1811).

Cells were seeded into 25 cm² flasks at 80% confluency. Five days later, flasks in triplicate received either no compound, serial dilutions of 3TC alone, or serial dilutions of 3TC plus *N*-nonyl-DNJ. At 2, 4, and 6 days after addition of compound (with medium replacement on those days), the amount of hepatitis B virus (HBV) DNA in the culture medium was determined by PCR analysis of polyethyleneglycol-sedimented particles. Thus, in these experiments, enveloped particles were not distinguished from nucleocapsids. PCR-amplified products were resolved by agarose gel electrophoresis (1.5% agarose), and the 538 nucleotide fragment was quantified by band scanning (HP Jet Imager). The amount of HBV recovered from untreated cells is assumed to be 100%. Data from the 6-day time point are presented in Figure 1 as the average values from at least three separate flasks, and the standard error was never greater than 20%, with an average error of 12%.

For each of the three time point series tested, the combination of 3TC plus *N*-nonyl-DNJ was significantly more effective in inhibiting HBV secretion than either compound alone. Conclusions based upon PCR analysis alone make it difficult to assign precise IC-50 values. The extreme sensitivity and delicate nature of PCR, for example, may account for the inability to achieve greater than 90% inhibition of HBV by 3TC alone, even at 300nM. Every experiment included controls to assure that PCR was performed in a range of concentrations of DNA in which the reaction yields results proportional to the amount of DNA in the sample. Resolution is approximately 3-fold, i.e., 3-fold differences in DNA concentrations can be detected. The inability to consistently detect less than 3-fold differences probably explains the failure of 3TC alone to achieve 90% inhibition. This suggests that a very high standard of inhibition must be met for the PCR to detect inhibition. Consequently, the trend, over three separate time points, is clear: the combined effect of 3TC plus

N-nonyl-DNJ is greater than that of either compound alone, or the additive individual effects of each compound.

These data suggest that the IC-50 of 3TC has been moved from about 60 nM to about 0.48 nM when 0.016 μ g/ml

5 *N*-nonyl-DNJ is present.

Example 4

Anti-Hepatitis B Virus Effect of *N*-nonyl-DNJ Alone in a Woodchuck Model

10 In order to evaluate the efficacy of *N*-nonyl-DNJ in combination with 3TC (or other nucleoside or nucleotide analogs) against Hepatitis B virus in a woodchuck animal model, an monotherapy experiment using *N*-nonyl-DNJ alone was first conducted. This was necessary to determine if *N*-nonyl-DNJ has any anti-HBV effect in the woodchuck and,
15 if *N*-nonyl-DNJ has a beneficial effect, to design a combination study based on the dose-response relationship of this drug alone.

Therefore, five groups of four animals each (all groups had both sexes, all but the control had two of each
20 sex) were assigned to 0, 12.5, 25, 50, and 100 mg/kg/day with BID oral dosing. These were lab-reared wild animals. All animals were infected with woodchuck hepatitis virus (WHV) as neonates, and had been tested positive on serological tests for WHV surface antigen. Blood samples
25 were drawn one week prior to dosing (-1 week), immediately before dosing (0 weeks), weekly during dosing (1, 2, 3, and 4 weeks), and after the end of dosing (5, 6, 8, and 10 weeks).

There are two measures of drug efficacy: reduction in
30 total HBV DNA (measured by quantitative PCR), and reduction in HBV DNA from capsids with intact surface glycoproteins, which is the active form of the virus (measured by an ELISA-like immune precipitation assay followed by quantitative PCR). Cell culture experiments
35 with *N*-nonyl-DNJ demonstrated little or no effect of this

compound on total HBV DNA, but a marked effect on the immune precipitated DNA (IPDNA). Not surprisingly, the IPDNA assay is quite variable; as a partial compensation for this, four assay runs were conducted, each containing
5 samples from all animals, but different subsets of the study weeks.

To summarize the results, *N*-nonyl-DNJ had no effect on total HBV DNA measurements, which were essentially constant for all dose levels over the pre-dose and dosed
10 portions of the study. On the other hand, IPDNA levels were not constant over the study period. The low dose animals tended to have increasing levels of IPDNA over the dosing period (weeks 0-4), while high dose animals tended to have decreasing levels of IPDNA over the same period.
15 Fitting a straight line to each animal's weekly responses gave a significant difference in the slope of these lines due to either dose or plasma level of drug. The plasma levels of drug were also quite variable: animals with the lowest plasma levels in their dose group had lower plasma
20 levels than the animals with the highest plasma levels from the next lower dose group. There were no differences between responses of males and females on any of the measures.

Plasma Levels

25 There were no clear patterns in the changes in plasma levels of *N*-nonyl-DNJ which could be related to week of dosing or time since previous dose. Because the plasma levels within an animal seemed reasonably consistent during dosing, the median plasma level for each animal was
30 used for subsequent modeling. The plasma levels for each week of the dosing period are plotted for each animal vs. dose (a small amount of random noise is added to the dose level so points which would lie on top of each other on the plot can be distinguished) (Figure 2).

HBV DNA

The total HBV DNA levels were essentially constant over time within each animal (data not shown). There was a faint hint of a dose-response relationship with decreasing levels of virus with increasing levels of drug, except that three animals at the highest dose had very high virus levels. It is not possible to conclude that there is any relationship between dose of N-nonyl-DNJ and total HBV DNA. It is possible that there are two populations of animals, responders (such as animal r) and non-responders (animals i, m, and d), but more data would be required to permit a firm conclusion on this point.

Immune Precipitated HBV DNA

Substantial variation existed in the IPDNA assay, both between assay runs and within assay runs (data not shown). Even so, it was possible to observe and model a slope over weeks 0-4 which is generally increasing for low dose animals and decreasing for high dose animals. This change in slope was statistically significant ($p < 0.005$).

Before models are fitted to the data, a log transform was applied because: 1) the variation in IPDNA increases with increasing IPDNA values; the log transformation gives values with a nearly constant variation, and 2) it is expected that drug effects will appear as a constant multiplier of the IPDNA level. Because there are zero values of IPDNA, a small value (about 1/2 of the smallest non-zero value) was added to all values before the log transform.

Two approaches were used to model the changes in slope to week with dose of N-nonyl-DNJ: a linear modeling approach and a nonlinear model. Both approaches assume that the (linear) rate of change of the $\text{Log}(\text{IPDNA})$ measure over the dosing period is the "right" measure to reflect the effect of the drug on the virus. Both approaches are fit in stages, and the first stage is common to both

approaches. First, a simple straight line regression model is fit using weeks 0-4 to predict $\log(\text{IPDNA} + 10)$ separately for each animal by run combination. In the second stage, the response variable is the slope fitted in the first stage.

For the linear approach, a model is fit with slope to week as the response where run is considered a block, dose has a significant effect (almost all of this effect is due to a slope to dose), and the relevant error for testing the effect of dose is the variation among animals treated alike (after the adjustment for the runs as blocks). This is similar to using the calibration data within each run to first adjust each run's data to a common virus DNA concentration; the difference is that here the data from the woodchucks are used for the run adjustment rather than only the calibration data.

For the nonlinear approach, a four parameter logistic model is fit with the slope to week as the response and the dose as the predictor. Again, run is considered a block, but because no run has all weeks, it is not possible to fully reflect the blocking in the nonlinear approach. Even so, the nonlinear model yields an EC_{50} of 7.88 mg/kg/BID dose. The average maximum slope observed was 2.71 additional $\log(\text{IPDNA } \mu\text{g/mL})/\text{week}$, or an increase of about 150%/week, the average minimum slope observed with *N*-nonyl-DNJ is 0.31 fewer $\log(\text{IPDNA } \mu\text{g/mL})/\text{week}$, or about a decrease of about 25%/week. The slopes, the fitted model, the parameter estimates from the model, and the approximate standard errors for these parameters are all shown in Figure 3. The data indicate an approximate effective monotherapy dose of *N*-nonyl-DNJ in woodchucks of about 16 mg/kg/day. Whether in woodchucks or humans, the effective dose of both the *N*-alkyl-DNJ and nucleoside or nucleotide antiviral agent administered in combination therewith can be administered in two equal daily subdoses (i.e., B.I.D.).

Figures 2 and 3 show letters to indicate animals.
Table 2 shows two of the animal codes, the sex, and the dose.

TABLE 2

5

Animal Codes, Sex, and Dose

	<u>Animal Number</u>	<u>Letter Code</u>	<u>Sex</u>	<u>Dose</u>
	F95343	b	F	0
	M96364	n	M	0
	F96304	k	F	0
10	F96301	j	F	0
	M96285	h	M	6.25
	F96283	g	F	6.25
	F96391	o	F	6.25
	M96305	l	M	6.25
15	F96271	f	F	12.5
	M96256	e	M	12.5
	M96404	s	M	12.5
	F96392	p	F	12.5
	F96163	c	F	25
20	M96414	t	M	25
	F96393	q	F	25
	M95322	a	M	25
	M96286	i	M	50
	F96231	d	F	50
25	F96402	r	F	50
	M96363	m	M	50

Example 5Antiviral Study to Test the Activity of
N-nonyl-DNJ in Combination with 3TC
in a Woodchuck Model of Hepatitis B Virus Infection

5 The combined activity of N-nonyl-DNJ and the
nucleoside analog 3TC can be assessed using the woodchuck
model of hepatitis B virus infection. Twenty-eight
woodchucks with persistent woodchuck hepatitis virus (WHV)
infection can be utilized. Groups of woodchucks can be
10 treated orally with 3TC alone (s.i.d.), with N-nonyl-DNJ
alone (b.i.d.), or with combinations of the two drugs.
The antiviral activity of the individual drugs and
combinations can be assessed by measuring serum WHV DNA
during treatment, and comparing the results of treated
15 groups to placebo treated controls.

 Twenty-eight woodchucks with established persistent
WHV infection can be used, all of which were
experimentally infected with WHV during the first week of
life. All can be WHsAg positive at the time the study is
20 initiated.

 A total of eight experimental groups can be used.
Woodchucks in each group can be stratified on the basis of
gender, body weight, and age. 3TC can be administered
orally as an aqueous suspension of Epivir (Glaxo-Wellcome)
25 tablets one time per day. N-nonyl-DNJ can also be
administered orally in aqueous solution, in two divided
doses. Treatment with both drugs can be followed by the
administration of 4 to 5 mls of semisynthetic liquid
woodchuck diet to insure complete ingestion of the drugs.

30 The experimental groups can be as follows:

	Group ID	No.	3TC (mg/kg/day)	N-nonyl-DNJ (mg/kg/day)
	1	4	0.0	0.0
	2	3	3.0	0.0
5	3	3	9.0	0.0
	4	3	0.0	4.0
	5	3	0.0	12.0
	6	4	1.5	2.0
	7	4	4.5	6.0
10	8	4	9.0	12.0


Woodchucks can be anesthetized (50mg/kg ketamine, 5mg/kg zylazine), weighed, and blood samples obtained prior to initial treatment, at weekly intervals during the six week period of treatment, and at 1, 2, and 4 weeks following treatment. Serum can be harvested and divided into aliquots. One aliquot can be used for analysis of WHV DNA by dot blot hybridization and for WHsAg by ELISA. CBCs and clinical biochemical profiles can be obtained prior to treatment and at the end of treatment. A second aliquot can be maintained as an archive sample. Other aliquots of serum can be used for drug analysis and special WHV DNA analyses.

The invention being thus described, it will be obvious that the same can be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such

modifications and equivalents as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

What Is Claimed Is:

1. A method of treating a hepatitis virus infection in a mammal, comprising administering to said mammal a first amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



I

wherein:

- 10 R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C_1 to C_{20} , and

- 15 W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof,

- 20 wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.

2. The method of claim 1, wherein R is a branched or straight chain alkyl having a chain length of C_1 to C_{20} , and W, X, Y, and Z are each hydrogen.

3. The method of claim 2, wherein R is a straight chain alkyl having a chain length of C_1 to C_{20} .

4. The method of claim 3, wherein R is a straight chain alkyl having a chain length of C_2 to C_{14} .

5. The method of claim 4, wherein R is a straight chain alkyl having a chain length of C_6 to C_{12} .

6. The method of claim 5, wherein R is nonyl.

7. The method of claim 1, wherein R is a branched or straight chain alkyl having a chain length of C_1 to C_{20} , and W, X, Y, and Z are each alkanoyl.

8. The method of claim 7, wherein R is a straight chain alkyl having a chain length of C_1 to C_{20} .

9. The method of claim 8, wherein R is a straight chain alkyl having a chain length of C_2 to C_{14} .

10. The method of claim 9, wherein R is a straight chain alkyl having a chain length of C_6 to C_{12} .

11. The method of claim 10, wherein R is nonyl.

12. The method of claim 7, wherein said alkanoyl has a chain length of C_1 to C_{20} .

13. The method of claim 7, wherein said alkanoyl has a chain length of C_2 to C_{14} .

14. The method of claim 7, wherein said alkanoyl has a chain length of C_3 to C_{10} .

15. The method of claim 7, wherein said alkanoyl is butanoyl.

16. The method of claim 7, wherein R is nonyl and W, X, Y, and Z are each butanoyl.

17. The method of claim 1, wherein
R is a straight chain alkyl having a chain length of C₁ to C₂₀,

W, X, Y, and Z are each hydrogen, and
5 said antiviral compound is a nucleoside antiviral compound.

18. The method of claim 1, wherein
R is a straight chain alkyl having a chain length of C₁ to C₂₀,

W, X, Y, and Z are each butanoyl, and
5 said antiviral compound is a nucleoside antiviral compound.

19. The method of claim 1, wherein said
N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-hexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
5 N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
10 tetrabutyrates;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
15 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

- N*-(*n*-undecyl-)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl-)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
20 *N*-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
25 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
30 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
40 *N*-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
45 tetrabutyrates;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
50 *N*-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,

- tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
55 tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
60 *N*-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
65 tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
70 *N*-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
75 tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrate; and
80 *N*-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate, and

said nucleoside or nucleotide antiviral compound is
selected from the group consisting of:

- (+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
85 yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine (FTC);

- (-)-2',3', dideoxy-3'-thiacytidine [(-)-SddC];
- 90 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
- 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);
- 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluarcil (FMAU);
- 95 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
- 2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
- 2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
- 2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
- 100 2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
- 2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
- 2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
- 2',3'-dideoxy-3'-fluorothymidine (FddThd);
- 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
- 105 2',3'-dideoxy-beta-L-5-thiacytidine;
- 2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
- 2'-deoxy-3'-thia-5-fluorocytosine;
- 3'-amino-5-methyl-dexocytidine (AddMeCyt);
- 3'-azido-3'-deoxythymidine (AZT);
- 110 3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
- 9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;
- 9-(2-phosphonylmethoxyethyl)adenine (PMEA);
- acyclovir triphosphate (ACVTP);
- 115 D-carbocyclic-2'-deoxyguanosine (CdG);
- dideoxy-cytidine;
- dideoxy-cytosine (ddC);
- dideoxy-guanine (ddG);
- dideoxy-inosine (ddI);
- 120 E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
- fluoro-arabinofuranosyl-iodouracil;
- stavudine;
- 2-deoxy-3'-thia-5-fluorocytidine;
- 2',3'-dideoxy-guanine; and

125 2',3'-dideoxy-guanosine.

20. The method of claim 1, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and *N*-(*n*-nonyl)-1,5-dideoxy-
5 1,5-imino-D-glucitol, tetrabutyrates, and said nucleoside antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

21. The method of claim 20, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and said
5 nucleoside antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

22. The method of claim 1, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 0.1 mg/kg/day to about 100 mg/kg/day.

23. The method of claim 22, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 1 mg/kg/day to about 75 mg/kg/day.

24. The method of claim 23, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 5 mg/kg/day to about 50 mg/kg/day.

25. The method of claim 1, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 0.1 mg/person/day to about 500 mg/person/day.

26. The method of claim 25, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 10 mg/person/day to about 300 mg/person/day.


27. The method of claim 26, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 25 mg/person/day to about 200 mg/person/day.

28. The method of claim 27, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 50 mg/person/day to about 150 mg/person/day.

29. The method of claim 1, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 1 mg/person/day to about 50 mg/person/day.

30. The method of claim 1, wherein said hepatitis virus infection is a hepatitis B virus infection.

31. A method of treating a hepatitis B virus infection in a mammal, comprising administering to said mammal from about 0.1 mg/kg/day to about 100 mg/kg/day of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



I

wherein:

10 R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₁ to C₂₀, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

15 from about 0.1 mg/person/day to about 500 mg/person/day of a compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral, and mixtures thereof.


32. The method of claim 31, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol and *N*-(*n*-nonyl-)-1,5-dideoxy-
5 1,5-imino-D-glucitol, tetrabutyrates, and said nucleoside antiviral agent is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

33. The method of claim 32, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol.

34. A method of treating a hepatitis B virus infection in a human patient, comprising administering to

said human patient from about 0.1 mg/kg/day to about 100 mg/kg/day of *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol and from about 0.1 mg/person/day to about 500 mg/person/day of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

35. A composition, comprising an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



I

5 wherein:

R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₁ to C₂₀, and

10 W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof.

36. A pharmaceutical composition, comprising a first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:

wherein:

5 R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C_1 to C_{20} , and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and
10 trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof, and

15 a pharmaceutically acceptable carrier, diluent, or excipient.

37. The pharmaceutical composition of claim 36, wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.

38. The pharmaceutical composition of claim 36, wherein R is a branched or straight chain alkyl having a chain length of C_1 to C_{20} , and W, X, Y, and Z are each hydrogen.

39. The pharmaceutical composition of claim 38, wherein R is a straight chain alkyl having a chain length of C_1 to C_{20} .

40. The pharmaceutical composition of claim 39, wherein R is a straight chain alkyl having a chain length of C_2 to C_{14} .

41. The pharmaceutical composition of claim 40, wherein R is a straight chain alkyl having a chain length of C_6 to C_{12} .

42. The pharmaceutical composition of claim 41, wherein R is nonyl.
43. The pharmaceutical composition of claim 36, wherein R is a branched or straight chain alkyl having a chain length of C_1 to C_{20} , and W, X, Y, and Z are each alkanoyl.
44. The pharmaceutical composition of claim 43, wherein R is a straight chain alkyl having a chain length of C_1 to C_{20} .
45. The pharmaceutical composition of claim 44, wherein R is a straight chain alkyl having a chain length of C_2 to C_{14} .
46. The pharmaceutical composition of claim 45, wherein R is a straight chain alkyl having a chain length of C_6 to C_{12} .
47. The pharmaceutical composition of claim 46, wherein R is nonyl.
48. The pharmaceutical composition of claim 43, wherein said alkanoyl has a chain length of C_1 to C_{20} .
49. The pharmaceutical composition of claim 43, wherein said alkanoyl has a chain length of C_2 to C_{14} .
50. The pharmaceutical composition of claim 43, wherein said alkanoyl has a chain length of C_3 to C_{10} .
51. The pharmaceutical composition of claim 43, wherein said alkanoyl is butanoyl.

52. The pharmaceutical composition of claim 43, wherein R is nonyl and W, X, Y, and Z are each butanoyl.

53. The pharmaceutical composition of claim 36, wherein

R is a straight chain alkyl having a chain length of C_1 to C_{20} ,

5 W, X, Y, and Z are each hydrogen, and
said antiviral compound is a nucleoside antiviral compound.

54. The pharmaceutical composition of claim 36, wherein

R is a straight chain alkyl having a chain length of C_1 to C_{20} ,

5 W, X, Y, and Z are each butanoyl, and
said antiviral compound is a nucleoside antiviral compound.

55. The pharmaceutical composition of claim 36, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

- 5 N-(n-hexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
10 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
15 tetrabutyrates;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

- N*-(*n*-undecyl-)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl-)-1,5-dideoxy-1,5-imino-D-glucitol;
20 *N*-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
25 *N*-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
30 *N*-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
40 tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
45 *N*-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
50 tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,

- tetrabutyrates;
- 55 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
60 tetrabutyrates;
- N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- 65 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
70 tetrabutyrates;
- N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- 75 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
- N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
80 glucitol, tetrabutyrates; and
- N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates, and

said nucleoside or nucleotide antiviral compound is
selected from the group consisting of:

- 85 (+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine;
- (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
- (-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine (FTC);

- 90 (-)2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
iodocytosine triphosphate (FIACTP);
- 95 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
methyлуarcil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (CloddMeCyt);
- 100 2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (CloddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
- 105 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
- 110 3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (CloddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-
dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
- 115 acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
- 120 dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
stavudine;
2-deoxy-3'-thia-5-fluorocytidine;
- 125 2',3'-dideoxy-guanine; and

2',3'-dideoxy-guanosine.

56. The pharmaceutical composition of claim 36, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and *N*-(n-
5 nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate, and said nucleoside antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

57. The pharmaceutical composition of claim 56, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol.

58. The pharmaceutical composition of claim 36, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 0.1 mg to about 100 mg.

59. The pharmaceutical composition of claim 58, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 1 mg to about 75 mg.

60. The pharmaceutical composition of claim 59, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 5 mg to about 50 mg.

61. The pharmaceutical composition of claim 36, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 0.1 mg to about 500 mg.


62. The pharmaceutical composition of claim 61, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 10 mg to about 300 mg.

63. The pharmaceutical composition of claim 62, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 25 mg to about 200 mg.

64. The pharmaceutical composition of claim 63, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 50 mg to about 150 mg.

65. The pharmaceutical composition of claim 36, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 1 mg to about 50 mg.

66. A pharmaceutical composition for treating a hepatitis B virus infection in a mammal, comprising from about 0.1 mg to about 100 mg of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



I

wherein:

R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl
10 having a chain length of C₁ to C₂₀, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

from about 0.1 mg to about 500 mg of a compound
15 selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral, and mixtures thereof.

67. The pharmaceutical composition of claim 66, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of
5 *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol and *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates, and said nucleoside antiviral agent is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

68. The pharmaceutical composition of claim 67, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol.

69. A pharmaceutical composition for treating a hepatitis B virus infection in a human patient, comprising from about 0.1 mg to about 100 mg of *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol and from about 0.1 mg to
5 about 500 mg of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

ABSTRACT OF THE DISCLOSURE

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with
5 nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with
10 nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.





FIGURE 1







FIGURE 3

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
 - ☐ All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11". Pages _____ do not meet these requirements.
 - ☐ Papers are not flexible, strong, smooth, non-shiny, durable, and white.
 - ☐ Papers are not typewritten or mechanically printed in permanent ink on one side.
 - ☐ Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
 - ☐ Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
 - ☐ The drawings or copy of drawings are not suitable for electronic reproduction.
 - ☐ All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
 - ☐ Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) _____ are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) _____ are missing.
5. OTHER: NO DECLARATION